Prothrombin complex concentrate use in liver transplantation: an international survey of current practices
Authors' conclusion
There is high variability in PCC use among clinicians administering transfusion in patients undergoing liver transplantation perioperatively.
Study context
- Population
- Anesthesiologists, intensivists and surgeons caring for patients undergoing liver transplantation
- Participants
- 107 participants · 10 countries
- Outcome
- PCC usage patterns in coagulopathy management during liver transplant surgery
Methodological detailsinternational, multicentre, survey, Respondents primarily anesthesiologists (88%)
- International
- Multicentre
- Survey
- Respondents primarily anesthesiologists (88%)
Main finding
As reported in the abstract
PCC use
Prothrombin complex concentrate (PCC) used
42%
PCC avoided
28%
PCC reserved for rescue treatment
30%
Observational data: associations, not effects.
Further findings
Preferred first-line treatment for general coagulation factor deficiency
- Frozen plasma preferred
- 82%
- PCC preferred
- 16%
- Prefer to avoid plasma altogether
- 14%
Intraoperative transfusion guidance
- Viscoelastic testing preferred
- 85%
- No standardized transfusion algorithm at institution
- 43%
Perceived barriers
- Hesitancy to give PCC with perceived higher thromboembolism risk; strong hesitancy to give plasma with volume overload
Original publication
Prothrombin complex concentrate use in liver transplantation: an international survey of current practices. Can J Anaesth. Published 1 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →